| Summary: | 碩士 === 國防醫學院 === 公共衛生學研究所 === 99 === Background : Although the tubeculosis is an ancient disease, it still exists in the world. In order to control tuberculosis successfully, treatment of active TB and prevent latent TB infection from progressing to active TB is necessary, especially for the developed countries. The latent TB infection therapies include taking consecutive nine months of Isoniazid or four months of Rifampin. Due to the lack of related literature, this study investigates and evaluates the efficacy of latent TB infection treatment and provides as a reference to relevant departments for TB control.
Methods : This is a longitudinal study. The study subjects are clinically confirmed TB cases and latent TB infection cases whose QuantiFERON-TB Gold In tube (QFT-GIT) results are positive. This study was approved by the institutional ethical committee. The latent tuberculosis infection therapies include taking 300 mg isoniazid daily for nine month or 600 mg rifampin daily for 4 months. Clinically confirmed TB cases receive standard medical therapy. QFT-GIT is used to detect the INF-γ responses during treatment and 1 year after treatment completion follow-up. Statistical analysis was performed using Nonparametic test Mann-Whitney test and Wilcoxon sign rank test to analyze the variations of median INF-γ concentrations between different therapy groups in the treatment period.
Result : The concentration of INF-γ decreased after 6 month anti-TB treatment compared with that before treatment for active TB, although there is no significant difference. Furthermore, we found there is no significant difference after 4 month therapy of Rifampin or 9 month therapy of Isoniazid in the concentration of INF-γ for latent tuberculosis infection treatment. However, the concentration of INF-γ increases by time for those without latent TB infection treatment.
Conclusions : According to our study, the majority of subjects with latent TB infection treatment still have positive QFT-GIT results. We suggest further long-term follow-up to examine the drug kinetics of INF-γ responses.
|
|---|
